Close



Apr 16, 2024 04:05PM
Feb 6, 2024 04:13PM
Feb 6, 2024 04:05PM
Jan 23, 2024 04:05PM
Jan 22, 2024 05:01PM
Jan 22, 2024 05:00PM
Jan 8, 2024 05:25AM Exelixis (EXEL) Reports Prelim FY23 Results, Issues 2024 Guidance
Jan 7, 2024 04:00PM
Nov 1, 2023 04:26PM
Oct 18, 2023 04:05PM
Aug 21, 2023 01:00AM
Aug 1, 2023 04:11PM
Aug 1, 2023 04:05PM
Jul 18, 2023 04:05PM Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
May 31, 2023 12:30PM
May 9, 2023 04:13PM
May 9, 2023 04:05PM
May 7, 2023 11:30PM
May 1, 2023 05:08PM
Apr 25, 2023 04:05PM
Apr 5, 2023 06:06PM Exelixis Reiterates Commitment to Shareholder Value Creation
Apr 5, 2023 08:04AM
Apr 5, 2023 08:00AM
Feb 13, 2023 05:02PM
Feb 13, 2023 05:00PM
Feb 7, 2023 04:22PM
Feb 7, 2023 04:05PM
Jan 24, 2023 04:05PM Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
Jan 9, 2023 04:58AM
Jan 8, 2023 04:00PM
Nov 1, 2022 04:05PM
Oct 18, 2022 04:05PM
Aug 9, 2022 05:10PM
Aug 9, 2022 04:05PM
Jul 26, 2022 04:05PM Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
May 10, 2022 04:41PM
May 10, 2022 04:05PM
Apr 26, 2022 04:05PM
Feb 17, 2022 04:24PM
Feb 17, 2022 04:05PM
Feb 14, 2022 05:02PM
Feb 14, 2022 05:00PM Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal C
Feb 3, 2022 04:05PM
Jan 10, 2022 05:48AM
Jan 9, 2022 04:00PM
Nov 2, 2021 04:43PM
Nov 2, 2021 04:05PM
Oct 19, 2021 04:05PM
Sep 6, 2021 01:00PM Exelixis Statement on the Passing of Two Senior Executives
Aug 6, 2021 10:36AM

973,681 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All